OmicsDI
Toggle navigation
Browse
Submit Data
Databases
API
Advanced
Search
8
Results
Show all
Save search
Copy query
Show results for
Unknown
(8)
Publication Date
Release Date
2025
(4)
2024
(2)
2026
(1)
2022
(1)
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
Two-year outcomes of sirolimus-coated balloon angioplasty for coronary artery disease: the EASTBOURNE Registry.
Not available
S-EPMC11200662
|
biostudies-literature
Cite
High-Risk Coronary Plaques and Carotid Duplex Findings in Asymptomatic Patients Undergoing Primary Prevention Assessment.
Not available
S-EPMC12941285
|
biostudies-literature
Cite
An Italian real-world multicenter study of patients with refractory/relapsed functional high-risk multiple myeloma patients treated with second-line therapies.
Not available
S-EPMC12552284
|
biostudies-literature
Cite
Clinical Efficacy of Isatuximab Plus Carfilzomib and Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients.
Not available
S-EPMC11613624
|
biostudies-literature
Cite
A 24-week prospective, multicenter, real-world study on eptinezumab's effectiveness and safety in migraine prevention (EMBRACE II).
Not available
S-EPMC12058817
|
biostudies-literature
Cite
Safety and Efficacy of Subcutaneous Rituximab in Previously Untreated Patients with CD20+ Diffuse Large B-Cell Lymphoma or Follicular Lymphoma: Results from an Italian Phase IIIb Study.
Not available
S-EPMC8813238
|
biostudies-literature
Cite
Comparison of "IN-REC-SUR-E" and LISA in preterm neonates with respiratory distress syndrome: a randomized controlled trial (IN-REC-LISA trial).
Not available
S-EPMC11218154
|
biostudies-literature
Cite
Polymer-free versus biodegradable-polymer drug-eluting stent in patients undergoing percutaneous coronary intervention: an assessor-blind, non-inferiority, randomised controlled trial.
Not available
S-EPMC11684330
|
biostudies-literature
Cite
Previous
page
1 / 1
You're on page
1
Next
page
Sort
by:
Relevance
Page size
10
OmicsDI
is part of the ELIXIR infrastructure
OmicsDI is an Elixir interoperability service.
Learn more ›
Tweets